← Russell 3000 cross-section

FTRE Fortrea Holdings Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$1.8bn
Revenue TTM
$2.7bn
Net income TTM
$-85m
Free cash flow
$196m
Composite score
50.6
Sector rank
#1699

Valuation

P / E
EV / EBITDA
39.6
EV / sales
1.0
FCF yield
10.86%
Earnings yield vs 10-yr
-9.45pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3.2%
EBITDA margin
2.5%
ROE
-16.2%
ROIC
-0.8%
Revenue growth
-2.1%

Insider activity, last 90 days

Net open-market
$-4.43m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenues The Company’s revenues for the three months ended June 30, 2026 were $678.2, a decrease of 4.5% from revenues of $710.3 in the corresponding period in 2025. The change in revenues was due to a decrease in organic revenues of 4.9%, partially offset by favorable foreign currency translation of 0.4%. The 4.9% decrease in organic revenues was due to lower pass through costs as well as lower demand for our functional service provider business. These decreases were partially offset by an increase in our clinical pharmacology business, driven by an increase in net new business and study mix. …Fortrea Holdings Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →